LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 137

Search options

  1. Article ; Online: Nanotechnology in the basophil activation test.

    Giavina-Bianchi, Pedro

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

    2022  Volume 130, Issue 2, Page(s) 157–158

    MeSH term(s) Humans ; Basophil Degranulation Test ; Basophils ; Immunoglobulin E ; Nanotechnology ; Tetraspanin 30 ; Flow Cytometry
    Chemical Substances Immunoglobulin E (37341-29-0) ; Tetraspanin 30
    Language English
    Publishing date 2022-09-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1228189-x
    ISSN 1534-4436 ; 0003-4738 ; 1081-1206
    ISSN (online) 1534-4436
    ISSN 0003-4738 ; 1081-1206
    DOI 10.1016/j.anai.2022.09.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.136: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis.

    Giavina-Bianchi, Mara / Giavina-Bianchi, Pedro

    Einstein (Sao Paulo, Brazil)

    2021  Volume 19, Page(s) eRC6064

    Abstract: We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used ... ...

    Abstract We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used cyclosporine, azathioprine, methotrexate and oral corticosteroids for long periods, plus topical treatments with no adequate disease control. Skin lesions were constant and widespread, with frequent skin infections and very poor quality of life, with numerous physical and psychosocial consequences, such as dropping out of school activities due to severe itching, appearance and bullying. They also showed delayed growth and development. In 2018, dupilumab, an immunobiological agent, was approved for treatment of moderate to severe atopic dermatitis in adults and, in 2019, extended to the 12-17-year age group. Although it had already been approved by the Brazilian Health Surveillance Agency, the 200mg presentation (indicated for the weight of patients) was not available, with no expected arrival date. Therefore, weighing the risks and benefits of the situation of both, we chose to treat them with an adult dose (loading dose of 600mg subcutaneously, and 300mg subcutaneously every 2 weeks) despite the low weight. So far, they have received eight injections, showing significant improvement of disease and quality of life. There were no major adverse effects, only worsening of allergic conjunctivitis in one of them. The patients and their family are very satisfied, and we believe that the therapy has been successful.
    MeSH term(s) Adolescent ; Adult ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Brazil ; Child ; Dermatitis, Atopic/drug therapy ; Double-Blind Method ; Humans ; Injections, Subcutaneous ; Quality of Life ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
    Language Portuguese
    Publishing date 2021-05-10
    Publishing country Brazil
    Document type Case Reports
    ZDB-ID 2418293-X
    ISSN 2317-6385 ; 1679-4508
    ISSN (online) 2317-6385
    ISSN 1679-4508
    DOI 10.31744/einstein_journal/2021RC6064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?

    Giavina-Bianchi, Pedro / Kalil, Jorge

    The World Allergy Organization journal

    2021  Volume 14, Issue 4, Page(s) 100532

    Abstract: Vaccination against coronavirus is essential to minimize the impact of the COVID-19 pandemic. Rare cases of anaphylaxis associated with the mRNA COVID-19 vaccines are being described, and the mechanisms involved in these reactions are poorly understood. ... ...

    Abstract Vaccination against coronavirus is essential to minimize the impact of the COVID-19 pandemic. Rare cases of anaphylaxis associated with the mRNA COVID-19 vaccines are being described, and the mechanisms involved in these reactions are poorly understood. A potential culprit agent of these vaccine-induced anaphylaxis events is polyethylene glycol, which has been reported as a cause of anaphylaxis. However, a cause-effect association has not been demonstrated, and the cases of anaphylaxis to mRNA COVID-19 vaccines should be further investigated. In this scenario, the recommendations are inaccurate and can lead to misinterpretation. At the moment, a more accurate recommendation would be the contraindication of mRNA COVID-19 vaccines in patients with immediate hypersensitivity reaction to polyethylene glycol or polysorbate. Patients with history of anaphylaxis to other or unknown causes should be referred to an allergist-immunologist for further orientation.
    Language English
    Publishing date 2021-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2581968-9
    ISSN 1939-4551
    ISSN 1939-4551
    DOI 10.1016/j.waojou.2021.100532
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis

    Mara Giavina-Bianchi / Pedro Giavina-Bianchi

    Einstein (São Paulo), Vol

    2021  Volume 19

    Abstract: ABSTRACT We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had ... ...

    Abstract ABSTRACT We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used cyclosporine, azathioprine, methotrexate and oral corticosteroids for long periods, plus topical treatments with no adequate disease control. Skin lesions were constant and widespread, with frequent skin infections and very poor quality of life, with numerous physical and psychosocial consequences, such as dropping out of school activities due to severe itching, appearance and bullying. They also showed delayed growth and development. In 2018, dupilumab, an immunobiological agent, was approved for treatment of moderate to severe atopic dermatitis in adults and, in 2019, extended to the 12-17-year age group. Although it had already been approved by the Brazilian Health Surveillance Agency, the 200mg presentation (indicated for the weight of patients) was not available, with no expected arrival date. Therefore, weighing the risks and benefits of the situation of both, we chose to treat them with an adult dose (loading dose of 600mg subcutaneously, and 300mg subcutaneously every 2 weeks) despite the low weight. So far, they have received eight injections, showing significant improvement of disease and quality of life. There were no major adverse effects, only worsening of allergic conjunctivitis in one of them. The patients and their family are very satisfied, and we believe that the therapy has been successful.
    Keywords Dermatitis ; atopic/drug therapy ; Conjunctivitis ; allergic ; Immunosuppressive agents ; Severity of illness index ; Dermatologic agents ; Dupilumab ; Azathioprine ; Adolescent ; Efficacy ; Safety ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-05-01T00:00:00Z
    Publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Granulomas Induced by Botulinum Toxin.

    Giavina-Bianchi, Pedro / Giavina-Bianchi, Mara

    The journal of allergy and clinical immunology. In practice

    2019  Volume 8, Issue 5, Page(s) 1710–1711

    MeSH term(s) Adult ; Botulinum Toxins/adverse effects ; Female ; Granuloma/chemically induced ; Humans ; Laryngoscopy
    Chemical Substances Botulinum Toxins (EC 3.4.24.69)
    Language English
    Publishing date 2019-12-30
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2019.12.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7086: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.

    Giavina-Bianchi, Mara / Rizzo, Luiz Vicente / Giavina-Bianchi, Pedro

    Allergologia et immunopathologia

    2020  Volume 48, Issue 6, Page(s) 792–797

    Abstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by relapsing eczema and pruritus. Until the development of Dupilumab, a new monoclonal antibody targeting IL-4 and IL-13 receptors, the current treatment of severe cases was ... ...

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by relapsing eczema and pruritus. Until the development of Dupilumab, a new monoclonal antibody targeting IL-4 and IL-13 receptors, the current treatment of severe cases was based on immunosuppressant agents. Our main goal was to build a case series of five patients with severe atopic dermatitis, who were using immunosuppressive drugs with significant adverse effects and only partially controlled AD, and compare their symptoms, SCORAD index, treatment regimens, total and specific IgE, and blood cell count before and after the introduction of Dupilumab. SCORAD index and topical corticosteroids used on a daily basis had a significant decrease after 16 weeks of Dupilumab. Adverse effects were mild: conjunctivitis, local reaction and regional dermatosis. All patients with severe atopic dermatitis achieved better control of AD with Dupilumab than with immunosuppressive drugs. Adverse effects, secondary infections, total and specific IgE levels were greatly reduced.
    MeSH term(s) Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Dermatitis, Atopic/blood ; Dermatitis, Atopic/diagnosis ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/immunology ; Humans ; Immunoglobulin E/blood ; Immunoglobulin E/immunology ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Middle Aged ; Severity of Illness Index ; Treatment Outcome ; Young Adult
    Chemical Substances Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; Immunoglobulin E (37341-29-0) ; dupilumab (420K487FSG)
    Language English
    Publishing date 2020-04-02
    Publishing country Singapore
    Document type Comparative Study ; Journal Article
    ZDB-ID 193144-1
    ISSN 1578-1267 ; 0301-0546
    ISSN (online) 1578-1267
    ISSN 0301-0546
    DOI 10.1016/j.aller.2019.12.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1165: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Polyethylene Glycol Is a Cause of IgE-Mediated Anaphylaxis.

    Giavina-Bianchi, Pedro / Kalil, Jorge

    The journal of allergy and clinical immunology. In practice

    2019  Volume 7, Issue 6, Page(s) 1874–1875

    MeSH term(s) Anaphylaxis ; Humans ; Hypersensitivity, Immediate ; Immunoglobulin E ; Polyethylene Glycols ; Polysorbates
    Chemical Substances Polysorbates ; Immunoglobulin E (37341-29-0) ; Polyethylene Glycols (3WJQ0SDW1A)
    Language English
    Publishing date 2019-07-06
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2019.05.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7086: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Systemic Treatment for Severe Atopic Dermatitis.

    Giavina-Bianchi, Mara / Giavina-Bianchi, Pedro

    Archivum immunologiae et therapiae experimentalis

    2018  Volume 67, Issue 2, Page(s) 69–78

    Abstract: Atopic dermatitis (AD) is a chronic inflammatory, relapsing disease of the skin, characterized by intense pruritus, maculopapular or vesicular erythematous lesions and scaling, sometimes accompanied by oozing, crusts and/or lichenification that has a ... ...

    Abstract Atopic dermatitis (AD) is a chronic inflammatory, relapsing disease of the skin, characterized by intense pruritus, maculopapular or vesicular erythematous lesions and scaling, sometimes accompanied by oozing, crusts and/or lichenification that has a negative impact on patients' quality of life. Prevalence is higher in children, around 15%, and approximately 5% in adults. Before introducing systemic therapy, it is mandatory to review patients' adherence to the correct use of topical treatments (corticosteroids, calcineurin inhibitors or cresoborole) and/or phototherapy. Ensure that environmental measures are being taken care of, irritant or proven allergic substances are not in use and even if the diagnostic is correct. If all is being done and topical treatment with corticosteroid, emollients and phototherapy have not been sufficient to achieve a good control in AD of adults or children patients, it is time to consider systemic agents. Up to now, most of systemic treatments were based on immunosuppressive therapies, being cyclosporine A, the usually first choice for moderate-to-severe AD. Recently, biologic drugs have been developed and approved for AD, as dupilumab, and a whole new group of drugs is giving much hope for patients to have a better control of the disease with less side effects.
    MeSH term(s) Administration, Intravenous ; Adult ; Antibodies, Monoclonal/therapeutic use ; Child ; Cyclosporine/therapeutic use ; Dermatitis, Atopic/drug therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Immunotherapy/methods ; Quality of Life ; Receptors, Interleukin-4/immunology ; Skin/pathology
    Chemical Substances Antibodies, Monoclonal ; Immunosuppressive Agents ; Receptors, Interleukin-4 ; dupilumab (420K487FSG) ; Cyclosporine (83HN0GTJ6D)
    Language English
    Publishing date 2018-08-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 282209-x
    ISSN 1661-4917 ; 0004-069X
    ISSN (online) 1661-4917
    ISSN 0004-069X
    DOI 10.1007/s00005-018-0521-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 393: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report.

    Giavina-Bianchi, Mara Huffenbaecher / Giavina-Bianchi, Pedro / Rizzo, Luiz Vicente

    Einstein (Sao Paulo, Brazil)

    2019  Volume 17, Issue 4, Page(s) eRC4599

    Abstract: Case report of a patient with severe atopic dermatitis who showed a good response to dupilumab. She had already used two immunosuppressive agents, cyclosporine A and mycophenolate mofetil, for the treatment of atopic dermatitis with no proper control of ... ...

    Abstract Case report of a patient with severe atopic dermatitis who showed a good response to dupilumab. She had already used two immunosuppressive agents, cyclosporine A and mycophenolate mofetil, for the treatment of atopic dermatitis with no proper control of the disease. She had also been taking all measures to control severe cases of the disease: bath and environmental controls, topical potent corticosteroids and emollients. She presented constant pruritus and skin lesions, frequent skin infections e poor quality of life. She also developed depression due to her disease. Recently, dupilumab, a new biological agent, was approved for the treatment of moderate/severe atopic dermatitis in many countries, including Brazil. Dupilumab is a monoclonal antibody with a common alpha chain of interleukin (IL) 4 and IL-13 receptors, two cytokines involved in the Th2 profile immune response that promote atopic inflammation. In a pioneer way in Brazil, the patient initiated the treatment with an attack dose of 600mg subcutaneous of dupilumab and 300mg subcutaneous every other week. Up to now, she has taken four applications, presenting a great improvement of the disease and her quality of life. There were no adverse effects, nor in the injection site nor of other kind. Patient and her family are very satisfied, and the medical team evaluates that the treatment is being well succeed. The case report described here subsidizes the use of dupilumab in the treatment of severe atopic dermatitis refractory to use of immunosuppressive agents.
    MeSH term(s) Adolescent ; Antibodies, Monoclonal/administration & dosage ; Brazil ; Dermatitis, Atopic/drug therapy ; Female ; Humans ; Immunosuppression ; Immunosuppressive Agents/administration & dosage ; Injections, Subcutaneous ; Interleukin-13 ; Interleukin-4 ; Quality of Life ; Severity of Illness Index
    Chemical Substances Antibodies, Monoclonal ; IL4 protein, human ; Immunosuppressive Agents ; Interleukin-13 ; Interleukin-4 (207137-56-2) ; dupilumab (420K487FSG)
    Language Portuguese
    Publishing date 2019-07-10
    Publishing country Brazil
    Document type Case Reports
    ZDB-ID 2418293-X
    ISSN 2317-6385 ; 1679-4508
    ISSN (online) 2317-6385
    ISSN 1679-4508
    DOI 10.31744/einstein_journal/2019RC4599
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Improving the Management of Hereditary Angioedema.

    Giavina-Bianchi, Pedro / Kalil, Jorge

    Clinics (Sao Paulo, Brazil)

    2018  Volume 73, Page(s) e354

    MeSH term(s) Angioedemas, Hereditary/diagnosis ; Angioedemas, Hereditary/therapy ; Brazil ; Humans ; Practice Guidelines as Topic
    Language English
    Publishing date 2018-05-17
    Publishing country United States
    Document type Editorial
    ZDB-ID 2182801-5
    ISSN 1980-5322 ; 1807-5932
    ISSN (online) 1980-5322
    ISSN 1807-5932
    DOI 10.6061/clinics/2018/e354
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 404: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top